Article

PDF
Access to the PDF text
Service d'aide à la décision clinique
Advertising



Journal Français d'Ophtalmologie
Volume 37, n° 10
pages 780-786 (décembre 2014)
Doi : 10.1016/j.jfo.2014.06.003
Received : 4 April 2014 ;  accepted : 11 June 2014
Choroidal neovascularization associated with extensive macular atrophy with pseudodrusen-like appearance
Néovascularisation choroïdienne dans l’atrophie maculaire extensive avec pseudodrusen
 

Figure 1




Figure 1 : 

Case # 1 before treatment–right eye (RE). Color fundus picture of right eye (RE) (A) and left eye (B) showing macular atrophy. Note the hemorrhage on the RE (arrow). Fluorescein Angiograph early (C) and late phase (D) of the RE (July 2011) demonstrating a cystoid macular edema (CME) (arrowhead) due to an actively leaking supero-macular type 2 choroidal neovascularization (arrow). Indocyanine green angiograph early (E) and late phase (F) of the RE. Horizontal (G) optical coherence tomography scan through the macula of the RE showing CME (small arrow), subretinal fluid (asterisks) and the fibrovascular lesion (arrowheads).


Figure 2




Figure 2 : 

Case # 1 after treatment–Right eye (RE). Fluorescein Angiograph early (A) and late phase (B) of the right eye (RE) (October 2011) showing resolution of cystoid macular edema (CME) after three intravitreal injections of ranibizumab. Horizontal (C) optical coherence tomography scan through the macula of the RE showing disappearance of CME and subretinal fluid.


Figure 3




Figure 3 : 

Case # 2 before treatment–left eye (LE). Color fundus picture of right eye (A) and left eye (LE) (B), and infrared frame and fundus autofluorescence of the LE (C and D) showing macular atrophy. Fluorescein Angiograph early (E) and late phase (F) of the LE showing an actively leaking infero-temporo-macular type 2 choroidal neovascularization (CNV) (arrow). Indocyanine green angiography, early (G) and late phase (H) of the LE. Horizontal optical coherence tomography scan through the macula of the LE (June 2007) (I) showing cystoid macular edema (small arrows), and the fibrovascular lesion (arrowheads) due to the actively leaking infero-macular type 2 CNV.


Figure 4




Figure 4 : 

Case # 2 after treatment–left eye (LE). Autofluorescence (A) and Multicolor® fundus picture (B) of LE showing progression of the macular atrophy. Fluorescein angiograph, early (C) and late phase (D) of the LE showing resolution of infero-temporo-macular exudation. Indocyanine green angiograph early (E) and late phase (F) of the LE. Horizontal optical coherence tomography scan through the macula of the LE after 8 intravitreal injections of ranibizumab (December 2012) (G) showing resolution of cystoid macular edema.


Figure 5




Figure 5 : 

Case # 3 before treatment–right eye (RE). Color fundus picture of RE (A) and left eye (B) showing macular atrophy. Fluorescein angiograph, early (C) and late phase (D) of the RE (March 2005) showing an actively leaking supero-macular type 2 choroidal neovascularization (CNV) (arrow). Horizontal optical coherence tomography scan through the macula of the RE (E) showing cystoid macular edema (small arrows), subretinal fluid (asterisks), and the fibrovascular lesion (arrowhead) due to the actively leaking supero-macular type 2 CNV.


Figure 6




Figure 6 : 

Case# 3 after treatment–right eye (RE). Multicolor® fundus picture of RE (A) and left eye (B) showing the macular atrophy, with the laser photocoagulation scar located superiorly to the macula on the RE. Fluorescein angiograph, early (C) and late phase (D) of the RE (December 2012) demonstrating resolution of exudative signs. Indocyanine green angiograph early (E) and late phase (F) of the RE. Horizontal optical coherence tomography scan through the macula of the RE (December 2012) (G) showing resolution of subretinal fluid and cystoid macular edema after one focal laser photocoagulation and 2 intravitreal injections of ranibizumab.

EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline